DNA Polymerase Delta 1 Catalytic Subunit (POLD1) as a Prognostic Factor in Clear Cell Renal Cell Carcinoma Patients
暂无分享,去创建一个
[1] Shuai Zhao,et al. Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma , 2021, Frontiers in Genetics.
[2] N. Vogelzang,et al. Biomarkers in renal cell carcinoma: Are we there yet? , 2021, Asian journal of urology.
[3] Zhijie Liang,et al. Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression , 2021, Frontiers in Oncology.
[4] Lemeng Zhang,et al. Multiple microarray analyses identify key genes associated with the development of Non-Small Cell Lung Cancer from Chronic Obstructive Pulmonary Disease , 2021, Journal of Cancer.
[5] Y. Pavlov,et al. DNA Polymerases at the Eukaryotic Replication Fork Thirty Years after: Connection to Cancer , 2020, Cancers.
[6] Tariq Ahmad Masoodi,et al. POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer , 2020, Endocrine connections.
[7] B. Drozdzowska,et al. Correlation among different pathologic features of renal cell carcinoma: a retrospective analysis of 249 cases. , 2020, International journal of clinical and experimental pathology.
[8] Tariq Ahmad Masoodi,et al. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East , 2020, Molecular genetics & genomic medicine.
[9] C. Sundaram,et al. Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers , 2020, Urology annals.
[10] Tariq Ahmad Masoodi,et al. Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region , 2019, Cancer Cell International.
[11] R. Xu,et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.
[12] Lorenzo Marconi,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.
[13] N. Agarwal,et al. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. , 2019, Annals of translational medicine.
[14] A. Ceribelli,et al. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC , 2018, AntiCancer Research.
[15] Guiqin Zhang,et al. Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia , 2018, Medicine.
[16] E. Golemis,et al. POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies , 2016, Gene.
[17] B. Delahunt,et al. Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors: Report From the International Society of Urologic Pathology Consensus Conference , 2014, The American journal of surgical pathology.
[18] K. Eckert,et al. Eukaryotic Replicative DNA Polymerases , 2014 .
[19] B. Delahunt,et al. Renal Tumors: Diagnostic and Prognostic Biomarkers , 2013, The American journal of surgical pathology.
[20] J. Cheville,et al. The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters , 2013, The American journal of surgical pathology.
[21] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[22] L. Loeb,et al. DNA polymerase delta in dna replication and genome maintenance , 2012, Environmental and molecular mutagenesis.
[23] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[24] B. Delahunt. Advances and controversies in grading and staging of renal cell carcinoma , 2009, Modern Pathology.
[25] F. Erdoğan,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.
[26] W. Remmele,et al. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.